Antichelicobacter therapy in the context of increasing bacterial resistance

A modern strategy for the treatment of diseases associated with Helicobacter pylori is mandatory inclusion in scheme antibiotics, as well considering level bacterial resistance to main components therapy. In Ukraine, infection some areas can reach about 80%, so prevalence peptic ulcer, atrophic gastritis and other gastrointestinal tract extremely high all sections population. Topical our country use standard triple antyhelicobacter therapy, which includes: proton pump inhibitor combination clarithromycin + amoxicillin. Such therapy lasting 10 or 14 days allows completely free from pylori, prevent further development pathological process on mucous membrane. This tactic successfully growth incidence gastric lymphoma, cancer stomach, reduce likelihood complications ulcers.